Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Francois Dhainaut

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 21, 2005
Underlying disorders and their impact on the host response to infectionJean-Francois Dhainaut, Yann-Erick Claessens, Jonathan Janes, et al.
Critical Care Medicine|February 6, 2004
Only activated protein C treatment and not protein C has demonstrated an improvement in survival in severe sepsisS Betty Yan, Jean-Francois Dhainaut, Hans Peter Schwarz, et al.
Critical Care (London, England)|June 10, 2003
The PIRO concept: R is for responseHerwig Gerlach, Jean-Francois Dhainaut, Stephan Harbarth, et al.
The American Journal of Emergency Medicine|October 9, 2007
Aspiration pneumonitis and Newton's law of gravitationGuillaume Der Sahakian, Franck Perruche, Aurélie Dabreteau, et al.
Critical Care Medicine|February 9, 2005
Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failureJean-Francois Dhainaut, Andrew F Shorr, William L Macias, et al.
Clinical Pharmacology and Therapeutics|October 19, 2002
Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsisWilliam L Macias, Jean-Francois Dhainaut, Sau Chi Betty Yan, et al.
Critical Care Medicine|January 11, 2005
Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trialPierre-Francois Laterre, Howard Levy, Gilles Clermont, et al.
Critical Care (London, England)|June 20, 2006
Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcomeAndrew F Shorr, Gordon R Bernard, Jean-Francois Dhainaut, et al.
Critical Care Medicine|December 16, 2004
Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsisWilliam L Macias, Benoit Vallet, Gordon R Bernard, et al.
Intensive Care Medicine|August 7, 2010
Statistical analysis plan of PROWESS SHOCK study, B Taylor Thompson, V Marco Ranieri, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 21, 2005
Underlying disorders and their impact on the host response to infectionJean-Francois Dhainaut, Yann-Erick Claessens, Jonathan Janes, et al.
Critical Care Medicine|February 6, 2004
Only activated protein C treatment and not protein C has demonstrated an improvement in survival in severe sepsisS Betty Yan, Jean-Francois Dhainaut, Hans Peter Schwarz, et al.
Critical Care (London, England)|June 10, 2003
The PIRO concept: R is for responseHerwig Gerlach, Jean-Francois Dhainaut, Stephan Harbarth, et al.
The American Journal of Emergency Medicine|October 9, 2007
Aspiration pneumonitis and Newton's law of gravitationGuillaume Der Sahakian, Franck Perruche, Aurélie Dabreteau, et al.
Critical Care Medicine|February 9, 2005
Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failureJean-Francois Dhainaut, Andrew F Shorr, William L Macias, et al.
Clinical Pharmacology and Therapeutics|October 19, 2002
Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsisWilliam L Macias, Jean-Francois Dhainaut, Sau Chi Betty Yan, et al.
Critical Care Medicine|January 11, 2005
Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trialPierre-Francois Laterre, Howard Levy, Gilles Clermont, et al.
Critical Care (London, England)|June 20, 2006
Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcomeAndrew F Shorr, Gordon R Bernard, Jean-Francois Dhainaut, et al.
Critical Care Medicine|December 16, 2004
Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsisWilliam L Macias, Benoit Vallet, Gordon R Bernard, et al.
Intensive Care Medicine|August 7, 2010
Statistical analysis plan of PROWESS SHOCK study, B Taylor Thompson, V Marco Ranieri, et al.
Pageof 2